Patent intelligence · US
US 12083098
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
Patent details — US 12083098
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 10, 2024
- Expiration
- Sep 5, 2044
- Applicant
- ACTUATE THERAPEUTICS INC.
- Claims
- 8
- CPC classes
- A61K, A61K31/404, A61K31/407, A61K9/0073
Quick answer
US 12083098 (Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACTUATE THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/404, A61K31/407, A61K9/0073, A61P, A61P11/00
More from ACTUATE THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11980607
Methods of treating malignant lymphoproliferative disorders
granted -
US 11510904
Methods of treating malignant lymphoproliferative disorders
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted
Frequently asked questions
What is US patent 12083098?
US 12083098 (Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors) is held by ACTUATE THERAPEUTICS INC.. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12083098?
ACTUATE THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12083098 expire?
Our index shows an expiration date of Sep 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.